Literature DB >> 23015149

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.

Shishir Rastogi1, Ramakant Kumar, Sukesh Rao Sankineani, Kanniraj Marimuthu, Laxman Rijal, Shyam Prakash, Divesh Jalan, Shah Alam Khan, Mehar C Sharma.   

Abstract

PURPOSE: A prospective study was undertaken to evaluate the diagnostic and prognostic significance of serum levels of vascular endothelial growth factor (VEGF) in patients with primary localised osteosarcoma.
METHODS: Serum VEGF levels were measured by an enzyme-linked immunosorbent assay (ELISA) in blood samples collected prechemotherapy, postchemotherapy, and postsurgery in 40 patients with histologically proven primary osteosarcoma. Comparison was made between serum VEGF level of healthy controls (n = 10) and prechemotherapy patient sera to evaluate its diagnostic potential. Serum VEGF levels of patients with and without metastasis were compared. Immunohistochemical staining was done to establish the correlation between serum and tissue VEGF expression. The Kaplan-Meier curve was used for survival analysis
RESULTS: No significant relationship was observed between serum VEGF levels and age, gender, tumour size, local recurrence or histopathological subtypes of osteosarcoma. We observed significantly raised mean serum VEGF in patient sera compared with healthy controls (p = 0.001). Significant fall in mean serum VEGF level was observed following chemotherapy (p = 0.001). Patients who developed metastases had significantly higher serum VEGF levels compared with the nonmetastatic group (P = 0.001). Serum VEGF levels correlated well with VEGF expression in tissues.
CONCLUSION: Serum VEGF levels might prove to be of diagnostic, predictive and prognostic value in patients with primary osteosarcoma, although further studies with larger sample size and longer follow-up is needed to support the hypothesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015149      PMCID: PMC3479274          DOI: 10.1007/s00264-012-1663-x

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  27 in total

1.  Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma.

Authors:  Y H Lee; T Tokunaga; Y Oshika; R Suto; K Yanagisawa; M Tomisawa; H Fukuda; H Nakano; S Abe; A Tateishi; H Kijima; H Yamazaki; N Tamaoki; Y Ueyama; M Nakamura
Journal:  Eur J Cancer       Date:  1999-07       Impact factor: 9.162

Review 2.  Clinical implications of circulating angiogenic factors in cancer patients.

Authors:  R T Poon; S T Fan; J Wong
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

3.  Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.

Authors:  B D Smith; G L Smith; D Carter; C T Sasaki; B G Haffty
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

4.  Quantification of angiogenesis stimulators in children with solid malignancies.

Authors:  H Pavlakovic; V Von Schütz; J Rössler; E Koscielniak; W Havers; L Schweigerer
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

5.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors.

Authors:  G Holzer; A Obermair; M Koschat; O Preyer; R Kotz; K Trieb
Journal:  Med Pediatr Oncol       Date:  2001-06

6.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.

Authors:  S A Stacker; C Caesar; M E Baldwin; G E Thornton; R A Williams; R Prevo; D G Jackson; S Nishikawa; H Kubo; M G Achen
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

7.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

Authors:  T Mäkinen; L Jussila; T Veikkola; T Karpanen; M I Kettunen; K J Pulkkanen; R Kauppinen; D G Jackson; H Kubo; S Nishikawa; S Ylä-Herttuala; K Alitalo
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

8.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.

Authors:  M Skobe; T Hawighorst; D G Jackson; R Prevo; L Janes; P Velasco; L Riccardi; K Alitalo; K Claffey; M Detmar
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

Review 9.  VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.

Authors:  Quan Zhou; Yong Zhu; Zhansheng Deng; Haitao Long; Shaoxian Zhang; Xingli Chen
Journal:  Surg Oncol       Date:  2011-03       Impact factor: 3.279

10.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.

Authors:  K Werther; I J Christensen; H J Nielsen
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

View more
  13 in total

1.  Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Authors:  N Habel; M Vilalta; O Bawa; P Opolon; J Blanco; O Fromigué
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

2.  Comment on Zhuang YF et al.: impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.

Authors:  Jinlong Ma; Ling Fang; Feng Zhang
Journal:  Tumour Biol       Date:  2014-08-12

3.  Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.

Authors:  Christoph J Laux; Gundula Berzaczy; Michael Weber; Susanna Lang; Martin Dominkus; Reinhard Windhager; Iris-Melanie Nöbauer-Huhmann; Philipp T Funovics
Journal:  Int Orthop       Date:  2014-11-30       Impact factor: 3.075

Review 4.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

5.  Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.

Authors:  Yanfeng Zhuang; Meiyang Wei
Journal:  Tumour Biol       Date:  2014-02-11

6.  High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.

Authors:  Fei Hu; Xi-Fu Shang; Wei Wang; Wei Jiang; Ce Fang; Dong Tan; Hang-Cheng Zhou
Journal:  Int J Exp Pathol       Date:  2016-03-30       Impact factor: 1.925

7.  Increased invasiveness of osteosarcoma mesenchymal stem cells induced by bone-morphogenetic protein-2.

Authors:  Xiao Yang; Ya-ping Wang; Feng-xiang Liu; Ke Zeng; Ming-quan Qian; Gang Chen; Lei Shi; Guo-xing Zhu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-03-22       Impact factor: 2.416

8.  Correlation between the expression of vegf and survival in osteosarcoma.

Authors:  André Mathias Baptista; André Ferrari De França Camargo; Renée Zon Filippi; Cláudia Regina Gomes Cardim Mendes De Oliveira; Raymundo Soares De Azevedo Neto; Olavo Pires De Camargo
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

9.  A case report of apatinib in treating osteosarcoma with pulmonary metastases.

Authors:  Yong Zhou; Wengeng Zhang; Fan Tang; Yi Luo; Li Min; Wenli Zhang; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

10.  Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients.

Authors:  Zhao Dong-Ju; Xiao Ai-Ju; Tian Yun-Jiao; Zhang Ming-Qiu
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.